VITILIGO

This study tests an oral medication called upadacitinib to see if it can safely and effectively restore skin color in people with non-segmental vitiligo, a condition where the immune system attacks pigment cells. About 540 adults and teens will receive either the drug or a placeb…

This study tests whether adding a cream of tacrolimus or tyrosine to standard narrowband UVB light therapy helps restore skin color in adults with vitiligo. About 67 participants will receive both creams on different patches and be followed for 3 months. The goal is to see which …

This study tests whether taking dexamethasone (a steroid) on two fixed days each week for 3 months can stop active vitiligo from spreading in children aged 4 to 9. Researchers will monitor skin activity, growth, bone age, and side effects like blood sugar changes. The goal is to …

This study tests an ointment called MH004 in 156 people aged 12 to 65 with non-segmental vitiligo, a condition causing white patches on the skin. The goal is to see if it safely helps restore color, especially on the face, over 24 weeks. Participants apply the ointment and are mo…

This study tests an experimental drug called SHR0302Base in 155 adults with stable nonsegmental vitiligo, a condition where white patches appear on the skin. The goal is to see if the drug can safely restore at least 50% of color to the face and neck over several months. Particip…

This study tests a daily pill called ritlecitinib in adults and teens with non-segmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the medicine can maintain or improve skin color over 52 weeks. Participants who already completed a year of …

This study tests whether a daily cream containing rapamycin can help bring back skin color in people with vitiligo. Twenty participants apply the cream to one patch of skin and a placebo to another for six months. Doctors check for repigmentation and side effects.

This early-phase study tests a new drug called DR-01 in adults with alopecia areata (patchy hair loss) or vitiligo (white patches on skin). The main goals are to check safety and see if the drug can improve hair regrowth or skin color. About 81 participants will receive the drug,…

This early-stage trial tests a new drug called TEV-53408 in 38 adults with vitiligo, a condition that causes white patches on the skin. The main goal is to see if the drug is safe. Participants receive injections for 24 weeks and are followed for over a year. This study does not …

This study is creating a large registry of up to 15,000 adults and children with inflammatory skin conditions like eczema, psoriasis, and vitiligo. Researchers will follow participants over time to see how treatments work in everyday medical practice and track any side effects. T…

This study looks at how a specific gene (TRPM2) and an inflammation-related protein (NLRP3) are linked in people with vitiligo, a condition that causes white patches on the skin. Researchers will compare blood samples from 60 adults with vitiligo and healthy volunteers to see if …